Please ensure Javascript is enabled for purposes of website accessibility

What to Like (and Dislike) About Clover Health's Q1 Results

By Keith Speights – Updated May 17, 2021 at 5:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medicare-focused company delivered strong top-line growth but a deteriorating bottom line.

There has been a dark cloud hovering over Clover Health Investments (CLOV -5.56%) since a short-seller made several allegations against the Medicare insurance technology company in February. Those allegations sparked a wave of class action lawsuits. Shares of Clover Health have plunged more than 50% year to date.

Clover announced its first-quarter results before the market opened on Monday. While there was some good news, it wasn't enough to serve as a major catalyst for the health insurance stock: Shares rose around 1% in early trading. Here are the highlights of Clover Health's Q1 update.

Stethoscope over Medicare enrollment form.

Image source: Getty Images.

By the numbers

Clover Health reported revenue in the first quarter of $200.3 million. This reflected a 21% increase from the prior-year period revenue total of $165.5 million. It also blew past the Wall Street consensus revenue estimate of $166.2 million.

The company announced a net loss in the first quarter of $48.4 million. In the prior-year period, Clover posted a net loss of $28.2 million.

Clover generated a Q1 adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) loss of $76.2 million. The health insurer delivered an adjusted EBITDA loss of $21.7 million in the same quarter of 2020.

Behind the numbers

The good news for Clover Health in Q1 was that the company reported record revenue. This was fueled by an 18% year-over-year increase in Medicare Advantage membership.

Clover Health president and chief technology officer Andrew Toy said the company's partnership with Walgreens is "off to a great start." Under this collaboration, which began in the second half of 2020, Clover's platform is used by Walgreens health advisors to offer new services to Clover members.

However, with Clover's widening net loss there also was clearly some bad news. The company's medical care ratio (MCR) jumped to 107.6% in the first quarter of 2021 from 89.4% in the prior-year period, based on generally accepted accounting principles (GAAP). MCR measures medical costs as a percentage of premiums. Health insurers don't want their MCR ratios to be too high.

Clover's bottom line would have been much worse. The company recognized a gain of $85.5 million in Q1 related to the change in the fair value of the warrant liability related to its merger with Social Capital Hedosophia III.

Looking ahead

Clover projects sales of $810 million to $830 million for full-year 2021. The company thinks Medicare Advantage membership will reach 68,000 to 70,000 by year-end, a growth rate of 17% to 21%. 

Probably the biggest thing to watch with Clover's business is the progress of its direct contracting initiative, which allows it to move beyond Medicare Advantage into the original Medicare program. This is a much larger opportunity than Medicare Advantage. Clover thinks it will sign up between 70,000 and 100,000 Medicare beneficiaries by the end of this year.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Clover Health Investments. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clover Health Investments, Corp. Stock Quote
Clover Health Investments, Corp.
$1.70 (-5.56%) $0.10
Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
$31.40 (-0.47%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.